ET-02
Pharmaceutical compound
From Wikipedia, the free encyclopedia
ET-02, also known as RS-5441, is a drug which is under development for the treatment of alopecia and hair disorders.[1][2][3] It is taken orally or topical, with both routes being developed.[1] The drug's exact mechanism of action has not yet been disclosed.[1] In any case, it is said to target and restore hair follicle stem cells (HFSCs).[3] ET-02 was originated by Renascience and is now under development by Eirion Therapeutics.[3][1][2] As of July 2025, it is in phase 1 clinical trials for alopecia and no recent development has been reported for hair disorders.[1][2] The drug was reported to promote significant hair growth after 4 weeks of treatment in humans in a phase 1 trial and to do so more rapidly than minoxidil.[3][1] As with its mechanism of action, the chemical structure of ET-02 does not yet appear to have been disclosed.[1]
| Clinical data | |
|---|---|
| Other names | ET02; RS-5441; RS5441 |
| Routes of administration | Oral, topical[1] |
| Drug class | Undefined (but targets and restores hair follicle stem cells)[1] |
